Liping Shi1, Long Xiao1, Baoli Heng1, Shijie Mo1, Weijun Chen1, Zexuan Su2. 1. Department of Urology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China. 2. Department of Urology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China. bolyheng@126.com.
Abstract
BACKGROUND: Placenta specific 8 (PLAC8) plays an important role in many different cellular processes and human diseases, including multiple types of cancer. However, the functional role of PLAC8 in clear cell renal cell carcinoma (ccRCC) has never been elucidated. METHODS: PLAC8 mRNA expression was investigated in 31 pairs of fresh ccRCC tumor tissues and matched adjacent non-tumor tissues by RT-qPCR and confirmed by analyzing the TCGA KRCC dataset which contains RNA-seq data of 534 ccRCC and 72 solid normal tissues. Protein level of PLAC8 expression was also investigated using immunohistochemistry in 129 ccRCC samples. Correlations with clinicopathological factors and overall survival were analyzed. To examine its effect on the biological activity, PLAC8 siRNAs were transfected into ccRCC cells. Cell proliferation was assessed by CCK8 cell viability assays, clone formation assays, and EdU incorporation assays. Cell invasion was examined using transwell assays. RNA sequencing was then performed to further elucidate the mechanisms by which PLAC8 regulates the cancer. RESULTS: PLAC8 expression was positively correlated with tumor size, metastasis, and clinical stage of ccRCC. Additionally, high PLAC8 expression was closely associated with a shorter overall survival time. Knockdown of PLAC8 with siRNAs significantly reduced the proliferation and invasion of RCC cells and increased the sensitivity of RCC cells to cisplatin. RNA-seq analysis revealed that knockdown of PLAC8 down-regulated the expression of a panel of inflammatory mediators, which suggested that PLAC8 is associated with the ccRCC inflammatory microenvironment. Patients with high expression of PLAC8 had a significantly higher number of infiltrative lymphocytes than patients with low expression of PLAC8. CONCLUSION: Our findings suggest that PLAC8 may be a potential prognostic indicator and therapeutic target for ccRCC.
BACKGROUND:Placenta specific 8 (PLAC8) plays an important role in many different cellular processes and human diseases, including multiple types of cancer. However, the functional role of PLAC8 in clear cell renal cell carcinoma (ccRCC) has never been elucidated. METHODS:PLAC8 mRNA expression was investigated in 31 pairs of fresh ccRCC tumor tissues and matched adjacent non-tumor tissues by RT-qPCR and confirmed by analyzing the TCGA KRCC dataset which contains RNA-seq data of 534 ccRCC and 72 solid normal tissues. Protein level of PLAC8 expression was also investigated using immunohistochemistry in 129 ccRCC samples. Correlations with clinicopathological factors and overall survival were analyzed. To examine its effect on the biological activity, PLAC8 siRNAs were transfected into ccRCC cells. Cell proliferation was assessed by CCK8 cell viability assays, clone formation assays, and EdU incorporation assays. Cell invasion was examined using transwell assays. RNA sequencing was then performed to further elucidate the mechanisms by which PLAC8 regulates the cancer. RESULTS:PLAC8 expression was positively correlated with tumor size, metastasis, and clinical stage of ccRCC. Additionally, high PLAC8 expression was closely associated with a shorter overall survival time. Knockdown of PLAC8 with siRNAs significantly reduced the proliferation and invasion of RCC cells and increased the sensitivity of RCC cells to cisplatin. RNA-seq analysis revealed that knockdown of PLAC8 down-regulated the expression of a panel of inflammatory mediators, which suggested that PLAC8 is associated with the ccRCC inflammatory microenvironment. Patients with high expression of PLAC8 had a significantly higher number of infiltrative lymphocytes than patients with low expression of PLAC8. CONCLUSION: Our findings suggest that PLAC8 may be a potential prognostic indicator and therapeutic target for ccRCC.
Authors: T S Tanaka; S A Jaradat; M K Lim; G J Kargul; X Wang; M J Grahovac; S Pantano; Y Sano; Y Piao; R Nagaraja; H Doi; W H Wood; K G Becker; M S Ko Journal: Proc Natl Acad Sci U S A Date: 2000-08-01 Impact factor: 11.205
Authors: Carlos Galaviz-Hernandez; Carole Stagg; Gustaaf de Ridder; Tetsuya S Tanaka; Minoru S H Ko; David Schlessinger; Ramaiah Nagaraja Journal: Gene Date: 2003-05-08 Impact factor: 3.688
Authors: Mirna Mourtada-Maarabouni; David Watson; Mamoona Munir; Farzin Farzaneh; Gwyn T Williams Journal: Curr Cancer Drug Targets Date: 2013-01 Impact factor: 3.428
Authors: Giorgia Maroni; Mahmoud A Bassal; Indira Krishnan; Chee Wai Fhu; Virginia Savova; Rapolas Zilionis; Valerie A Maymi; Nicole Pandell; Eva Csizmadia; Junyan Zhang; Barbara Storti; Julio Castaño; Riccardo Panella; Jia Li; Corinne E Gustafson; Sam Fox; Rachel D Levy; Claire V Meyerovitz; Peter J Tramontozzi; Kimberly Vermilya; Assunta De Rienzo; Stefania Crucitta; Daniela S Bassères; Marla Weetall; Art Branstrom; Alessandra Giorgetti; Raffaele Ciampi; Marzia Del Re; Romano Danesi; Ranieri Bizzarri; Henry Yang; Olivier Kocher; Allon M Klein; Robert S Welner; Raphael Bueno; Maria Cristina Magli; John G Clohessy; Azhar Ali; Daniel G Tenen; Elena Levantini Journal: Commun Biol Date: 2021-04-14